Kiniksa Pharmaceuticals (NASDAQ:KNSA) announces “early
evidence” of treatment response with mavrilimumab, an investigational
fully-human monoclonal antibody, in a treatment protocol in patients
with severe coronavirus 2019 pneumonia and hyperinflammation.
The objective was to reduce incidence of
progression of acute respiratory failure, the need of
mechanical ventilation, and the transfer to the intensive care unit.
All 6 patients treated with mavrilimumab showed resolution of fever and did not progress to mechanical ventilation.
The company plans to evaluate a Phase 2/3 clinical
development program pending regulatory feedback and data from treatment
experiences.
Kiniksa and its collaborators are planning to commence investigator-initiated studies in parallel.
https://seekingalpha.com/news/3556739-kiniksa-pharmas-mavrilimumab-shows-treatment-response-in-covidminus-19-patients-shares-up-39
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.